Nivalin. 5 mg. 1 ml.10 ampules
Nivalin. 5 mg. 1 ml.10 ampules
Content of one ampoule of 1 ml; 5 mg;
Galantamine hydrobromide 1 mg; 5 mg;
Neurology - traumatic injuries of the central nervous system, symptoms of cerebral palsy , diseases of the spinal cord ( myelitis , polio, polio form of tick-borne encephalitis ) Mononeuritis , polyneuritis , polyneuropathy, poliradikulonevriti with m - Guillain- Barre syndrome , idiopathic facial paresis , myopathies and enuresis nocturna.
Anesthesia and surgery - to eliminate the effect of non-depolarizing neuromuscular blockers in the treatment of postoperative paresis of the bladder and bowel .
Physiotherapy - applied iontophoretic neurological diseases of the peripheral nervous system.
Toxicology - poisoning holinolitichnoto drugs , morphine and its analogues.
Radiology - to facilitate the functional diagnosis of the gastro - intestinal tract and gall bladder.
Method of administration : parenteral / subcutaneous , intramuscular, intravenous /
The dosage and duration of treatment with Nivalin necessarily determined by the physician according to the condition of the patient. Treatment begins with the smallest effective dose and gradually increasing. The maximum single dose for adults is 10 mg subcutaneous and maximum daily dosages of 20 mg. Higher daily doses are recommended to be divided into two doses.
In children it is administered subcutaneously in daily doses of the following : 1 to 2 years old - 0,25 - 1,0 mg of 3 to 5 years - 0,50 - 5,0 mg of 6 to 8 years of age - 0.75 - 7,5 mg of 9 to 11 years old - 1,0 - 10,0 mg of 12 to 15 years old - 1,25 - 12,5 mg over 15 years - 12,5 - 20,0 mg
The duration of treatment is dependent on the characteristics and severity of the disease .
* Hypersensitivity to any component of the product , bronchial asthma , bradycardia , AV- block, angina, severe heart failure , epilepsy , hyperkinesia, severe renal or hepatic insufficiency
* Special warnings
In the treatment of patients with mild renal insufficiency application of Nivalin should be approached cautiously and in lower dosages based on creatinine clearance.
Therapy with galantamine can lead to loss of body weight.
The product should be used with caution in patients with difficulty in urinating or after a recent surgery of the prostate gland , as well as operations with general anesthesia .
In case of side effects in the implementation of Nivalin is necessary to reduce the daily dose or the treatment discontinued for 2-3 days and then continue with lower doses.
Nivalin should be used with caution in patients suffering from chronic obstructive pulmonary disease or peptic ulcer disease because of the possibility of intensification of complaints .
* Drug Interactions
Nivalin antagonizes the effect of morphine and its analogs with respect to their inhibitory effect on the respiratory center . Between Nivalin and M - holinolititsite ( atropine, homatropine ) ganglioblokerite ( benzoheksoniy , pentamin , pahikarpin ) non-depolarizing muscle relaxants ( tubocurarine , etc.). , Quinine and novokainamid exist antagonistic interactions. Aminoglycoside antibiotics ( gentamicin, amikacin ) can reduce the therapeutic effect of Nivalin on myasthenia gravis . The effect of depolarizing neuromuscular blocking agents ( suxamethonium ) may be prolonged by concomitant use of Nivalin .
Medicinal products that inhibit the enzyme CYP2D6 ( quinidine , paroxetine, fluoxetine) and CYP3A4 ( ketoconazole, Retrovir , erythromycin ) may affect the metabolism of galantamine and increase its plasma concentration.
Pregnancy and lactation Nivalin should not be used during pregnancy and also during lactation . * Adverse effects These may be muscarinic and nicotine . When applying higher doses and individual sensitivity more common side effects are: nausea , vomiting, diarrhea , abdominal pain, salivation , sweating, anorexia , fatigue, dizziness , headache, drowsiness and weight loss. Less commonly observed adverse reactions were insomnia , rhinitis , bradycardia , impaired vision , and urinary tract infection .
* Formulation and packaging
Ampoules of 1 mg / 1 ml; 2,5 mg / 1 ml; 5 mg / 1 ml; 10 mg / 1 ml and ten pieces in a blister pack . One or ten blister packs are placed in boxes.